EyePoint (EYPT) Receivables - Other (2020 - 2021)
EyePoint (EYPT) reported Receivables - Other of $414000.0 for Q4 2021, up 298.08% on a YoY basis from $104000.0 in Q4 2020, and up 298.08% sequentially from $104000.0 in Q4 2020.
EyePoint (EYPT) Receivables - Other (2020 - 2021) Analysis & Trends
EyePoint (EYPT) has 2 years of Receivables - Other data on file, last reported at $414000.0 in Q4 2021.
- For the quarter ending Q4 2021, Receivables - Other rose 298.08% year-over-year to $414000.0; the trailing twelve-month figure through Dec 2021 stood at $414000.0 (up 298.08% YoY), and the FY2021 full-year result was $414000.0, up 298.08% from the prior year.
- Receivables - Other rose to $414000.0 in Q4 2021, from $104000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $414000.0 in Q4 2021 to a low of $104000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 414,000.00 |
| Dec 31, 2021 | 414,000.00 |
| Dec 31, 2020 | 104,000.00 |
| Dec 31, 2020 | 104,000.00 |